Current evidence on the use of anakinra in COVID-19.

Elnaz Khani, Marzieh Shahrabi, Haleh Rezaei, Fariba Pourkarim, Hoda Afsharirad, Mohammad Solduzian

International immunopharmacology 2022 Oct

filter terms:

Despite the progressing knowledge in COVID-19 management, remdesivir is the only agent that got approval to inhibit viral replication. However, there are limited data about effective immunomodulatory agents to prevent cytokine release in COVID-19. Cytokine release syndrome in COVID-19 resembles secondary hemophagocytic lymphohistiocytosis, in which interleukin-1 (IL-1) plays a key role. Anakinra is the first recombinant IL-1 receptor antagonist studied for off-label use in COVID-19 treatment. This study reviews the current clinical evidence on the role of interleukin-1 in COVID-19-related cytokine storm, therapeutic effects, significant clinical concerns, and pros and cons of anakinra administration in the management of COVID-19 patients. In this review, four items are shown to be important for achieving the optimal therapeutic effects of anakinra in COVID-19 patients. These items include duration of treatment ≥ 10 days, doses ≥ 100 mg, intravenous administration, and early initiation of therapy. Also, anakinra might be more beneficial in the early stages of the disease when higher levels of cytokines are yet to be observed, which could prevent progression to severe illness and mechanical ventilation. Further studies are required to address the SARS-CoV-2 induced cytokine release syndrome and the role of anakinra in identifying ideal treatment approaches for COVID-19 patients based on their clinical status. Copyright © 2022 Elsevier B.V. All rights reserved.

Citation

Elnaz Khani, Marzieh Shahrabi, Haleh Rezaei, Fariba Pourkarim, Hoda Afsharirad, Mohammad Solduzian. Current evidence on the use of anakinra in COVID-19. International immunopharmacology. 2022 Oct;111:109075